FOXC1 and urinary bladder cancer: Indeed, the significant overlap between FOXC1 binding sites and increased chromatin accessibility in SP cells suggests that FOXC1 may act as a pioneer transcription factor in bladder cancer cells that transition to cisplatin resistance.